

Biotech Capital.

Biotech Capital (BTC) -ASX Announcement

5 May 2017

BIOIMPACT ENTERS INTO LICENSE AGREEMENT WITH RLS GLOBAL FOR CHLORASOLV®

Biotech Capital Limited (ASX:BTC) announced today that its wholly owned subsidiary BioImpact Pty Ltd has entered into an exclusive license and supply agreement with RLS Global AB of Sweden. The agreement, which is effective immediately, grants BioImpact the rights to distribute the wound care product ChloraSolv®, within Australia, New Zealand and select countries across the Asia Pacific region.

ChloraSolv is a topical gel, which is classified as a medical device. It is clinically proven to effectively clean and assist with the healing of chronic wounds. The method of treatment is simple and safe and shortens each treatment session and the time it takes for slow-healing wounds to heal. It represents a unique and modern approach to the effective treatment of hard-to-heal diabetic ulcers, venous stasis ulcers and pressure sores.

ChloraSolv is pending FDA and CE approvals, which are expected during 2018. BioImpact intends to commercialise ChloraSolv in select Asia Pacific countries during 2017 and to file for marketing approvals with the TGA and Medsafe during 2018.

The global wound care market is expected to reach US\$20.4B by 2021, up from US\$17.0B in 2016 and growing at a CAGR of 3.6% from 2016 to 2021. The factors driving the market growth include an aging population, government support in the form of funding for development of wound care products and an increasing incidence of chronic diseases such as diabetes and obesityⁱ.

Biotech Capital's Chairman Dr. Richard Treagus commented; "We are delighted to be partnering with RLS Global for the commercialisation of ChloraSolv in the Asia Pacific region. ChloraSolv is a novel and highly effective approach to chronic wound care. As a health issue, chronic wounds represent a very significant cost and quality of life burden for millions of patients worldwide each year."

About RLS Global AB

RLS Global is a Swedish medtech company based in Gothenburg. RLS Global develops and sells biochemical products and methods for treatment of some of the world's most common diseases. RLS Global has a portfolio of products including wound care product **Chlorasolv**® and dental products **Carisolv System**®, **Kindersolv**® and **Perisolv**®. The company is dedicated to help in the fight against antibiotic resistance.

Biotech Capital.

About ChloroSolv®

ChloroSolv is a topical gel applied directly to the wound. After application, the gel is allowed to work for less than 5 minutes after which the healthcare professional can easily remove dead and damaged tissue. ChloroSolv effectively cleanses the wound and reduces wound-related odours. Healthy tissue is not affected by the treatment. ChloroSolv's ability to clean the wound together with its antibacterial effect creates good conditions for healthy tissue to re-grow and eventually close the wound. The treatment is repeated 1-2 times a week until the wound is healed.

<http://www.chlorosolv.com>

ⁱ Marketsandmarkets.com May 2016

About Biotech Capital Limited

Biotech Capital is a listed entity on the ASX and is a Pooled Development Fund, registered under the Pooled Development Funds Act 1992. The company's strategy is to make active investments in life science businesses and late-stage product development opportunities that will benefit from greater access to development capital. The company has the longer-term objective of building a group of complimentary businesses that are entrepreneurial, innovative, globally focused and when operating together have the ability to generate better health outcomes and add value for its shareholders.

Under the Pooled Development Funds Act 1992, shareholders are entitled to concessionary tax treatment in Australia for income and capital gains derived in connection with their shareholding. Gains realised on the disposal of shares will not be included in an investor's assessable income in Australia. An investor will not be entitled to any deduction or capital loss on the sale of shares.

Unfranked dividends received by an Australian resident will be exempt from tax. Franked dividends will also be exempt from tax unless the shareholder elects to be taxed. An Australian corporate tax entity may credit its franking account (with franking credits attaching to a franked dividend), regardless of whether it has elected to treat the dividend as exempt or assessable income. Dividends paid to non-residents will not be subject to withholding tax. A shareholder or prospective shareholder should obtain their own tax advice rather than relying on this summary.

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Biotech Capital to be materially different from the statements in this announcement.

For more information, please contact:

Dr. Richard Treagus, Executive Chairman

rtreagus@biotechcapital.com.au

+61 417 520509